In GC, individuals with high ANOS1 expression exhibited low IC50 concentrations for 5-fluorouracil, dasatinib, and docetaxel, suggesting enhanced treatment outcomes (Fig. 11A–C). Here, ANOS1 is linked to gastric cancer.